Persons with NIDDM have abnormal oxygen consumption (VO2) responses to exercise even in the absence of clinical cardiovascular disease. We hypothesize that in persons with NIDDM, compared to nondiabetic persons, decreased maximal and dynamic cardiac output and/or A-VO2 responses are associated with the observed impaired VO2 responses. We also hypothesize that the decreased VO2 observed in NIDDM is associated with decreased levels of habitual physical activity level compared to control values. In addition, we hypothesize that exercise training will improve cardiovascular exercise performance and habitual physical activity level. Subjects will include 20 sedentary persons with uncomplicated NIDDM, 20 healthy persons of similar weight, age and activity level and 20 lean persons of similar age and activity level as the persons with NIDDM. We will measure the dynamic and maximal responses of VO2 cardiac output and A-VO2 difference (by direct Fick and hemodilution methods) during exercise in persons with NIDDM. Slowed maximal responses of cardiac output would suggest an impairment in oxygen delivery in NIDDM. Additionally, or alternatively, A-VO2 difference responses may be also be abnormal suggesting a peripheral impairment. To determine whether the decreased VO2max response observed in NIDDM is associated with decreased habitual physical activity level we will compare the three groups using doubly-labeled water techniques. A four month exercise training program will follow the testing procedures with the tests to be repeated upon completion. The importance of these studies is 1) to evaluate the underlying causes of the apparent cardiovascular abnormalities observed in uncomplicated NIDDM; 2) to evaluate the functional significance of these findings, and 3) to evaluate the modifiability of the responses. This project will enable further understanding of the effects of diabetes on cardiovascular function during exercise as well as the functional significance of exercise impairment in diabetes.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR000051-39
Application #
6414455
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1978-12-01
Project End
2001-11-30
Budget Start
Budget End
Support Year
39
Fiscal Year
2000
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Hayden, Kathleen M; Baker, Laura D; Bray, George et al. (2018) Long-term impact of intensive lifestyle intervention on cognitive function assessed with the National Institutes of Health Toolbox: The Look AHEAD study. Alzheimers Dement (Amst) 10:41-48
Shah, V N; Sippl, R; Joshee, P et al. (2018) Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance. Osteoporos Int 29:733-739
Jensen, Thomas; Bjornstad, Petter; Johnson, Richard J et al. (2018) Copeptin and Estimated Insulin Sensitivity in Adults With and Without Type 1 Diabetes: The CACTI Study. Can J Diabetes :
Dad, Taimur; Abebe, Kaleab Z; Bae, K Ty et al. (2018) Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 3:619-624
Millstein, Richard J; Pyle, Laura L; Bergman, Bryan C et al. (2018) Sex-specific differences in insulin resistance in type 1 diabetes: The CACTI cohort. J Diabetes Complications 32:418-423
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459

Showing the most recent 10 out of 1065 publications